Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Protocadherin beta-1 is a calcium-dependent cell-adhesion molecule, part of the clustered protocadherin gene family tandemly linked on chromosome 5. It is an integral plasma membrane protein composed of 6 extracellular cadherin domains and a unique cytoplasmic tail. These proteins are predominantly expressed in the nervous system and are believed to play a critical role in establishing and maintaining specific cell-cell neural connections, contributing to neural circuit development and synaptic specificity. The gene’s regulation involves epigenetic mechanisms, including methylation-dependent transcriptional repression. While its functions are inferred from broader protocadherin family studies, it is not currently targeted by approved drugs or used directly as a diagnostic biomarker. Disease associations include intellectual disability and some cancers, reflecting broader roles in nervous system development and pathophysiology.
Not applicable; no drugs are known to act directly on Protocadherin beta-1
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Protocadherin beta-1 (PCDHB1).